Source-grounded facts extracted from FENNEC PHARMACEUTICALS INC.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
FENNEC PHARMACEUTICALS INC. shareholders approved Ratification and adoption of Fennec's 2026 Equity Inducement Plan at the 2026-06-10 meeting.
“The resolution to ratify and approve the adoption of Fennec’s 2026 Equity Inducement Plan was approved based on the following vote:. Votes For 18,626,207 Votes Against 1,033,779 Abstentions 713,501 Broker Non-Votes 5,881,885”
FENNEC PHARMACEUTICALS INC. shareholders approved Approval of amendments to Corporation's 2020 Equity Incentive Plan at the 2026-06-10 meeting.
“The resolution to approve certain amendments to Corporation’s 2020 Equity Incentive Plan was approved based on the following vote: Votes For (1) 17,425,439 Votes Against 1,429,951 Abstentions 751,944 Broker Non-Votes 5,881,885”
FENNEC PHARMACEUTICALS INC. shareholders approved Advisory vote on the frequency of advisory votes on compensation at the 2026-06-10 meeting.
“The resolution to vote on the advisory vote on the frequency of advisory votes on compensation of Corporations named executive officers was approved based on the following vote: Votes For Evey One Year 18,235,648 Votes For Evey Two Years 2,326 Votes For Evey Three Years 2,086219 Abstentions 49,294”
FENNEC PHARMACEUTICALS INC. shareholders approved Advisory vote on executive compensation at the 2026-06-10 meeting.
“The resolution to vote on the advisory vote on executive compensation was approved based on the following vote: Votes For 19,326,750 Votes Against 336,060 Abstentions 710,677 Broker Non-Votes 5,881,885”
FENNEC PHARMACEUTICALS INC. shareholders approved Appointment of Haskell & White LLP as independent public accounting firm and authorization to fix remuneration at the 2026-06-10 meeting.
“The resolution to appoint Haskell & White LLP as independent public accounting firm of the Company and to authorize the Board of Directors to fix their remuneration was approved based on the following vote: Votes For 26,091,716 Votes Withheld 134,491 Votes Against 29,165 Broker Non-Votes 0”
FENNEC PHARMACEUTICALS INC. shareholders approved Election of five nominees to serve as directors at the 2026-06-10 meeting.
“The following five (5) nominees were elected to serve as directors”
Rostislav Raykov departed as Board member at FENNEC PHARMACEUTICALS INC..
“On April 27, 2026, Rostislav Raykov notified Fennec Pharmaceuticals Inc. (the "Company") of his desire to retire from the Company's Board of Directors (the "Board") and that he will not stand for re-election at the Company's 2026 annual meeting of shareholders (the "Annual Meeting").”
FENNEC PHARMACEUTICALS INC. reported the fourth quarter of 2025 results: revenue $13.8 million.
“For the fourth quarter of 2025, the Company recorded net product sales of $13.8 million compared to $7.9 million in the fourth quarter of 2024, representing an increase of approximately 75%.”
FENNEC PHARMACEUTICALS INC. reported the fiscal year ended December 31, 2025 results: revenue approximately $44.6 million.
“For the full fiscal year (FY) 2025, the Company recorded net product sales of approximately $44.6 million compared to $29.6 million in 2024, representing an increase of approximately 50%.”
Christiana Cioffi was appointed as Chief Strategy Officer at FENNEC PHARMACEUTICALS INC..
“Ms. Christiana Cioffi, MBA, as Chief Strategy Officer ("CSO"),”
Terry Evans was appointed as Chief Commercial Officer at FENNEC PHARMACEUTICALS INC..
“Mr. Terry Evans as Chief Commercial Officer ("CCO"),”
Pierre S. Sayad was appointed as Chief Medical Officer at FENNEC PHARMACEUTICALS INC..
“On October 28, 2024, Fennec Pharmaceuticals Inc.'s (the "Company") announced the appointments of Mr. Pierre S. Sayad, PhD, M.S., as Chief Medical Officer ("CMO"),”
Jeffrey S. Hackman was appointed as Director at FENNEC PHARMACEUTICALS INC..
“the Company announced the appointment of Jeffrey S. Hackman as CEO and a member of the Board.”
Jeffrey S. Hackman was appointed as Chief Executive Officer at FENNEC PHARMACEUTICALS INC..
“the Company announced the appointment of Jeffrey S. Hackman as CEO and a member of the Board.”
Rostislav Raykov departed as Chief Executive Officer at FENNEC PHARMACEUTICALS INC..
“the Company announced the departure of Rostislav Raykov from his position as the Company’s Chief Executive Officer”
Adrian Haigh departed as Chief Operating Officer at FENNEC PHARMACEUTICALS INC..
“On June 30, 2024, Adrian Haigh departed from his position as Fennec Pharmaceuticals Inc.’s (the "Company") Chief Operating Officer”
FENNEC PHARMACEUTICALS INC. reported financial results for full year and fourth quarter 2023.
“Fennec Pharmaceuticals Inc. issued a news release announcing full year and fourth quarter financial results for the period ended December 31, 2023.”
FENNEC PHARMACEUTICALS INC. entered into License and Supply Agreement with Norgine Pharma UK Limited valued at €40 million (effective 2024-03-15).
“On March 15, 2024, Fennec Pharmaceuticals, Inc., a Delaware corporation (“Fennec”) and wholly owned subsidiary of Fennec Pharmaceuticals Inc. (the “Company”), entered into a License and Supply Agreement (the “Agreement”) with Norgine Pharma UK Limited (“Norgine”)”
FENNEC PHARMACEUTICALS INC. reported Full-year 2023 results: revenue approximately $20.7 to $21.2 million.
“• Full-year 2023 net revenues are expected to be approximately $20.7 to $21.2 million.”
FENNEC PHARMACEUTICALS INC. reported Fourth quarter 2023 results: revenue approximately $9.2 to $9.7 million.
“• Fourth quarter 2023 net revenues are expected to be approximately $9.2 to $9.7 million, which represents approximately a 41-49% increase over the third quarter of 2023.”
FENNEC PHARMACEUTICALS INC. incurred convertible notes of $5,000,000 with Petrichor Opportunities Fund I LP at greater of (a) US Prime Rate or (b) three and one-half percent (3.5%), plus the maturing August 19, 2027.
“On December 4, 2023, the Company closed a third tranche under the SPA in the amount of $5,000,000 and issued the Investor a Note in the same amount (the “Third Closing Note”).”
FENNEC PHARMACEUTICALS INC. entered into Third Closing Note with Petrichor Opportunities Fund I LP valued at issued $5,000,000 senior secured floating rate convertible note, convertible at $7.89 per share, mat (effective 2023-12-04).
“On December 4, 2023, the Company closed a third tranche under the SPA in the amount of $5,000,000 and issued the Investor a Note in the same amount (the “Third Closing Note”).”
FENNEC PHARMACEUTICALS INC. entered into First Amendment to Securities Purchase Agreement with Petrichor Opportunities Fund I LP valued at extended draw period to December 31, 2024 for remaining $15,000,000 (effective 2023-12-04).
“Also on December 4, 2023, the Company entered into a First Amendment to the Securities Purchase Agreement (the “SPA Amendment”) with the Investor, which, among other things, extends the period that the Company may draw the remaining $15,000,000 under the SPA from December 31, 2023 to December 31, 2024.”
FENNEC PHARMACEUTICALS INC. reported the third quarter ended September 30, 2023 results: revenue $6.5 million, net income $1.9 million ($0.07 per share), EPS $0.07 per share.
“EXHIBIT 99.1 Exhibit 99.1 FENNEC PHARMACEUTICALS ANNOUNCES THIRD QUARTER 2023 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE ~ PEDMARK ® Net Product Revenue of $6.5 Million, a 96% Increase Compared to Second Quarter ~ ~ Strong Commercial Uptake Underscoring Significant Unmet Medical Need ~ ~ Received Approval in October 2023 by the Medicines and”
Adrian Haigh was appointed as Chief Operating Officer at FENNEC PHARMACEUTICALS INC..
“Mr. Haigh had accepted the appointment as Chief Operating Officer.”
Adrian Haigh departed as Director at FENNEC PHARMACEUTICALS INC..
“Adrian Haigh had stepped down from the the position of Director of Fennec Pharmaceuticals Inc.”
FENNEC PHARMACEUTICALS INC. reported second quarter ended June 30, 2023 results: revenue $3.3 million, net income $5.4 million ($0.21 per share), EPS ($0.21 per share).
“2023 and provided a business update. “During the second quarter, we continued to make strong progress with the U.S. commercial launch of PEDMARK ® , delivering net revenue of $3.3 million, which is a 98% increase in net revenue over the first quarter of 2023. These results reflect strong growth in patient starts and new account orders,” said Rosty Raykov, chief”
Adrian Haigh was appointed as Chief Commercial Officer at FENNEC PHARMACEUTICALS INC..
“In the same press release it was announced that Mr. Haigh had accepted the appointment as Chief Commercial Officer.”
Adrian Haigh departed as Director at FENNEC PHARMACEUTICALS INC..
“Adrian Haigh had stepped down from the the position of Director of Fennec Pharmaceuticals Inc.”
FENNEC PHARMACEUTICALS INC. shareholders approved Advisory vote on executive compensation at the 2023-06-12 meeting.
“3. The resolution to vote on the advisory vote on executive compensation was approved based on the following vote: Votes For 15,855,506 Votes Against 134,025 Abstentions 5,087 Broker Non-Votes 5,292,156”
FENNEC PHARMACEUTICALS INC. shareholders approved Ratification of appointment of Haskell & White LLP as independent public accounting firm at the 2023-06-12 meeting.
“2. The resolution to appoint Haskell & White LLP as independent public accounting firm of the Company and to authorize the Board of Directors to fix their remuneration was approved based on the following vote: Votes For 21,129,213 Votes Withheld 157,561 Votes Against 0 Broker Non-Votes 0”
FENNEC PHARMACEUTICALS INC. shareholders approved Election of six nominees to serve as directors at the 2023-06-12 meeting.
“1. The following six (6) nominees were elected to serve as directors, each to serve until the next annual meeting of shareholders of the Company or until their respective successor shall have been duly elected or duly approved: Name of Nominee Votes For Votes Withheld Broker Non-Votes Dr. Khalid Islam 15,932,888 61,730 5,292,156 Adrian Haigh 15,931,496 63,122 5,292,156 Chris A. Rallis 15,931,887 62,731 5,292,156 Marco Brughera 15,935,618 59,000 5,292,156 Jodi Cook 15,932,047 62,571 5,292,156 Rostislav Raykov 15,924,786 69,832 5,292,156”
Shubh Goel resigned as Chief Commercial Officer at FENNEC PHARMACEUTICALS INC..
“On January 31, 2022 Fennec Pharmaceuticals Inc. announced the resignation of Chief Commercial Officer, Shubh Goel.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.